Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

Eur J Clin Microbiol Infect Dis. 1995 Nov;14(11):949-53. Unique Identifier : AIDSLINE MED/96246479
Sanchez-Quijano A; Andreu J; Gavilan F; Luque F; Abad MA; Soto B; Munoz J; Aznar JM; Leal M; Lissen E; Department of Internal Medicine, Virgen del Rocio University; Hospital, Seville, Spain.

Abstract: The aim of the present study was to investigate the possible role of human immunodeficiency virus (HIV) infection in the natural course of chronic hepatitis C. Seventy-six adult patients with chronic parenterally acquired hepatitis C virus (HCV) infection examined from 1989 to 1993 were enrolled; of these 32 (42.1%) were HIV positive and 44 (57.9%) were HIV negative. Serum HCV RNA quantitation was carried out by polymerase chain reaction in a well-characterized group (n = 20; 11 HIV positive and 9 HIV negative). Distribution of histological findings in liver biopsies from both HIV-infected and noninfected patients was similar. However, within 15 years after initial HCV infection, 8 of 32 (25%) HIV-positive patients developed cirrhosis, in comparison with only 2 of 31 (6.5%) patients in the HIV-negative group (p < 0.05); similar incidences of cirrhosis were found in both patient groups within 5 and 10 years after HCV infection. Most of the HIV-negative cirrhotic patients (9 of 11) developed cirrhosis in a time interval longer than 15 years. Finally, HCV load was almost ten times higher (1 10-fold dilution) in the HIV-positive group, but this difference did not reach statistical significance in this small study population. These results suggest that HIV infection can alter the natural course of chronic parenterally acquired hepatitis C, causing an unusually rapid progression to cirrhosis.

Keywords: Adult Cohort Studies Disease Progression Female Hepatitis C/BLOOD/*COMPLICATIONS/DIAGNOSIS Hepatitis, Chronic Active/BLOOD/*COMPLICATIONS/DIAGNOSIS Human HIV Infections/*COMPLICATIONS/DIAGNOSIS/VIROLOGY HIV-1/PATHOGENICITY Liver Cirrhosis/COMPLICATIONS/DIAGNOSIS Male Risk Factors JOURNAL ARTICLE
961030
M96A1374

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .